<DOC>
	<DOCNO>NCT02639871</DOCNO>
	<brief_summary>There curative treatment available today Huntington disease ( HD ) despite identification mutate gene 20 year ago . Nonetheless , safe promising therapeutic strategy target brain energy metabolism become available . In view small effect size clinical parameter HD , robust neuroimaging biomarkers reflect brain energy metabolism therefore urgently need good assess potential therapeutic target mitochondrion , especially Krebs cycle . Identifying biomarkers presymptomatic phase HD also provide unique window therapeutic intervention , use proof-of-concept real challenge tomorrow 's medicine : prevention neurodegeneration HDeNERGY observational study consist transfer method preclinical clinical study application HD . HDeNERGY aim optimize MRI/MRS method study dynamic brain energy metabolism . At CENIR ( Centre de neuro-imagerie et de recherche , Paris ) determination creatine kinase rate first validate healthy volunteer ( n=20 ) apply select cohort early affect HD patient ( n=20 ) , presymptomatic individual ( n=20 ) control ( n=20 ) together method previously validate HD patient ( Mochel et al. , 2012b ) determine ratio inorganic phosphate ( Pi ) / phosphocreatine ( PCr ) visual stimulation presymptomatic individual . The Chemical Exchange Saturation Transfer ( CEST ) method 3T clinical scanner CENIR first validate healthy volunteer ( n=20 ) apply select cohort early affect HD patient ( n=20 ) , presymptomatic individual ( n=20 ) control ( n=20 ) . The cerebral synthesis rate creatine phosphate brain glutamate concentration pH value compare control , HD patient HD presymptomatic individual , correlate clinical parameter ( age , BMI , UHDRS ) .</brief_summary>
	<brief_title>Dynamic Neuroimaging Biomarkers Huntington 's Disease</brief_title>
	<detailed_description>Compelling evidence indicate key role energy defect neurodegenerative disease ( NDs ) . These defect would constitute extremely informative functional biomarkers disease state progression . Such functional biomarkers could use readout therapeutic efficacy clinical trial , especially drug target brain energy metabolism . Magnetic Resonance Imaging ( MRI ) Magnetic Resonance Spectroscopy ( MRS ) likely promise approach validate brain biomarkers link energy metabolism . However , exist method allow `` static '' measure metabolites concentration offer fragmented vision brain energy metabolism NDs . The validation novel `` dynamic '' method urgently need . Our project address challenge Huntington disease ( HD ) . Our study observational study consist transfer method preclinical clinical study application HD . This study comprise two period : - Period 1 : transfer 31P saturation transfer CEST method preclinical clinical MRS/MRI platform validation method healthy individual ; - Period 2 : compare brain metabolic marker early individual affect HD , presymptomatic individual control , use 31P saturation transfer CEST method . The primary objective : Using 31P saturation transfer CEST method , primary objective compare novel metabolic biomarkers control HD carrier ( patient presymptomatic individual ) . Assessment criterion : Comparison control , HD patient HD presymptomatic individual cerebral synthesis rate creatine phosphate brain glutamate concentration pH value The secondary objective : - To develop/optimize 31P MRS/CEST method study dynamic brain energy metabolism humans - To improve understand `` model '' nature energy deficit HD - To look correlation brain energy profile clinical score . Assessment criterion : - Validation 31P MRS CEST method healthy volunteer . - Combination integration 31P MRS CEST data order obtain model energy deficit HD . - Correlations creatine phosphate synthetic rate clinical parameter ( age , BMI , UHDRS ) ; correlation glutamate concentration clinical parameter ; correlation pH value clinical parameter . Ancillary study : The investigator wish compare brain energy parameter ( creatine phosphate synthetic rate , glutamate concentration , pH value ) systemic metabolic marker ( profile plasma metabolite obtain metabolomic lipidomic study ) .</detailed_description>
	<mesh_term>Huntington Disease</mesh_term>
	<criteria>Inclusion criterion Healthy Volunteers Period 1 : At least 18 year age Signature inform consent Covered social security Participants Period 2 : At least 18 year age Signature inform consent Covered social security Presymptomatic individual : Positive genetic test CAG repeat length &gt; 39 HTT gene , UHDRS score &lt; 5 Early affected patient : Positive genetic test CAG repeat length &gt; 39 HTT gene UHDRS score 5 40 BMI 18 30 Noninclusion criterion Healthy Volunteers Period 1 : Contraindications MRI ( claustrophobia , metallic material implant ) History severe head injury Participation another trial Pregnancy breastfeed Inability understand information protocol Persons deprive liberty judicial administrative decision Adult subject legal protection unable consent . Unwillingness inform case abnormal MRI Participants Period 2 : Contraindications MRI ( claustrophobia , metallic material implant ) Additional psychiatric neurological condition / Additional major comorbidities History severe head injury Participation another trial Pregnancy breastfeed Inability understand information protocol Persons deprive liberty judicial administrative decision Adult subject legal protection unable consent . Unwillingness inform case abnormal MRI Treatment tetrabenazine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Huntington disease</keyword>
	<keyword>Neuroimaging metabolic biomarker</keyword>
</DOC>